story of the week
Tumor Mutational Burden Associated With Outcomes in Patients With Advanced Solid Tumors Treated With Pembrolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study
Lancet Oncol 2020 Sep 10;[EPub Ahead of Print], A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, K Nakagawa, HC Chung, HL Kindler, JA Lopez-Martin, WH Miller, A Italiano, S Kao, SA Piha-Paul, JP Delord, RR McWilliams, DA Fabrizio, D Aurora-Garg, L Xu, F Jin, K Norwood, YJ BangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.